MCID: OCL009
MIFTS: 55

Ocular Cancer

Categories: Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Ocular Cancer

MalaCards integrated aliases for Ocular Cancer:

Name: Ocular Cancer 12 15
Eye Carcinoma 12 15 71
Eye Neoplasms 44 71
Eye Neoplasm 12 17
Eye Cancer 54 42
Malignant Eye Neoplasm 12
Neoplasm of Eye Proper 12
Malignant Tumor of Eye 71
Carcinoma of Eye 12
Ocular Carcinoma 12
Neoplasm of Eye 12
Ocular Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2174 DOID:295
ICD9CM 34 190.8
MeSH 44 D005134
NCIt 50 C3030 C6079
SNOMED-CT 67 126995000 188277006
ICD10 32 C69.9
UMLS 71 C0015414 C0153632 C0496836 more

Summaries for Ocular Cancer

MedlinePlus : 42 Cancer of the eye is uncommon. It can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. If the cancer starts inside the eyeball it's called intraocular cancer. The most common intraocular cancers in adults are melanoma and lymphoma. The most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. Cancer can also spread to the eye from other parts of the body. Treatment for eye cancer varies by the type and by how advanced it is. It may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.

MalaCards based summary : Ocular Cancer, also known as eye carcinoma, is related to ocular melanoma and familial retinoblastoma, and has symptoms including eye manifestations An important gene associated with Ocular Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Carmustine and Povidone-iodine have been mentioned in the context of this disorder. Affiliated tissues include eye, bone marrow and brain, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 An ocular cancer that has material basis in abnormally proliferating cells, derives from epithelial cells and arises from the tissues that cover structures located in the eye.

Wikipedia : 74 Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer).... more...

Related Diseases for Ocular Cancer

Diseases related to Ocular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)
# Related Disease Score Top Affiliating Genes
1 ocular melanoma 32.2 MC1R IL2 BRCA2
2 familial retinoblastoma 30.8 TP53 RB1 MDM2
3 retinal cancer 30.6 TP53 RB1 MYC MIR199A1 MIR17 MDM2
4 merkel cell carcinoma 30.5 TP53 RB1 MYC
5 basal cell carcinoma 30.4 XPA TP53 SOX2 MDM2 MC1R IL2
6 melanoma 30.4 TP53 RB1 MYC MLANA MIR17 MDM2
7 mature teratoma 30.4 TP53 POU5F1 H2AC18
8 sarcoma 30.4 TP53 RB1 POU5F1 MYC MDM2
9 leiomyosarcoma 30.4 TP53 RB1 MYC MLANA MDM2
10 adenocarcinoma 30.3 TP53 RB1 MYC MDM2 BRCA2 APC
11 rhabdomyosarcoma 30.3 TP53 RB1 MYC MDM2 BRCA2 ABCG2
12 lung cancer susceptibility 3 30.3 U2AF1 TP53 RB1 MYC MIR17 H2AC18
13 t-cell acute lymphoblastic leukemia 30.3 U2AF1 TP53 MYC IL2
14 malignant astrocytoma 30.3 U2AF1 TP53 SOX2 MYC MIR199A1 MIR17
15 neuroblastoma 30.3 TP53 SOX2 POU5F1 MYC MIR17 MDM2
16 connective tissue disease 30.2 U2AF1 TP53 MIR199A1 MIR17 IL2 H2AC18
17 medulloblastoma 30.2 TP53 SOX2 RB1 POU5F1 MYC MIR17
18 skin melanoma 30.2 U2AF1 TP53 MYC MLANA MIR199A1 MDM2
19 melanoma, uveal 30.1 U2AF1 TP53 PLG MYC MLANA MIR199A1
20 leukemia, acute lymphoblastic 30.1 U2AF1 TP53 RB1 MYC MIR199A1 MIR17
21 soft tissue sarcoma 30.1 TP53 MDM2
22 eye carcinoma in situ 11.0
23 intraocular lymphoma 10.9
24 xeroderma pigmentosum, variant type 10.8
25 bap1 tumor predisposition syndrome 10.8
26 vulvar adenocarcinoma 10.6 TP53 RB1
27 ring chromosome 7 10.6 TP53 MDM2
28 suppressor of tumorigenicity 3 10.6 TP53 RB1 MYC
29 anal carcinoma in situ 10.6 TP53 MYC
30 hepatic angiomyolipoma 10.6 RB1 MYC MLANA
31 peritoneum cancer 10.6 TP53 H2AC18 BRCA2
32 pediatric systemic lupus erythematosus 10.6 MYC MIR17 MDM2
33 gliomatosis cerebri 10.6 TP53 RB1 MDM2
34 anal squamous cell carcinoma 10.6 TP53 MDM2 APC
35 mutagen sensitivity 10.6 XPA TP53 BRCA2
36 actinic cheilitis 10.6 TP53 MDM2
37 spermatogenic failure, y-linked, 1 10.6 POU5F1 MYC
38 nodular malignant melanoma 10.6 TP53 MLANA MC1R
39 megaesophagus 10.6 TP53 MYC CD8A
40 inflammatory bowel disease 28 10.6 SOX2 POU5F1 MYC
41 basaloid lung carcinoma 10.6 TP53 BRCA2
42 inflammatory myofibroblastic tumor 10.6 TP53 RB1 MYC MDM2
43 diffuse midline glioma, h3 k27m-mutant 10.6 TP53 H2AC18 BRCA2
44 necrotizing fasciitis 10.6 PLG IL2 H2AC18
45 richter's syndrome 10.6 TP53 MYC MIR17
46 breast carcinoma in situ 10.6 TP53 MYC H2AC18 BRCA2
47 lung adenoma 10.6 TP53 MYC H2AC18
48 connective tissue benign neoplasm 10.6 TP53 MLANA MDM2 H2AC18
49 ovarian cystadenocarcinoma 10.6 TP53 MYC MIR17 BRCA2
50 cardia cancer 10.6 TP53 MIR17 MDM2

Graphical network of the top 20 diseases related to Ocular Cancer:



Diseases related to Ocular Cancer

Symptoms & Phenotypes for Ocular Cancer

UMLS symptoms related to Ocular Cancer:


eye manifestations

MGI Mouse Phenotypes related to Ocular Cancer:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 ABCG2 APC BRCA2 CD8A IL2 MC1R
2 hematopoietic system MP:0005397 10.37 ABCG2 APC BRCA2 CD8A COL4A2 IL2
3 integument MP:0010771 10.37 ABCG2 APC BRCA2 CD8A COL4A2 MC1R
4 endocrine/exocrine gland MP:0005379 10.36 APC BRCA2 CD8A COL4A2 IL2 MDM2
5 immune system MP:0005387 10.36 ABCG2 APC BRCA2 CD8A COL4A2 IL2
6 digestive/alimentary MP:0005381 10.31 APC BRCA2 COL4A2 IL2 MDM2 MYC
7 craniofacial MP:0005382 10.23 APC COL4A2 MC1R MDM2 MYC RB1
8 embryo MP:0005380 10.21 APC BRCA2 COL4A2 MDM2 MYC POU5F1
9 neoplasm MP:0002006 10.18 APC BRCA2 COL4A2 IL2 MC1R MDM2
10 nervous system MP:0003631 10.18 ABCG2 APC BRCA2 CD8A COL4A2 MDM2
11 liver/biliary system MP:0005370 10.16 ABCG2 APC IL2 MDM2 MYC PLG
12 limbs/digits/tail MP:0005371 10.13 APC BRCA2 COL4A2 MC1R MDM2 MYC
13 hearing/vestibular/ear MP:0005377 10.08 APC COL4A2 MC1R MYC RB1 SOX2
14 muscle MP:0005369 10.03 APC COL4A2 MDM2 MYC RB1 SOX2
15 normal MP:0002873 9.96 ABCG2 APC BRCA2 CD8A MDM2 MYC
16 no phenotypic analysis MP:0003012 9.92 IL2 MC1R MDM2 MLANA MYC RB1
17 pigmentation MP:0001186 9.81 APC MC1R MDM2 MLANA MYC RB1
18 reproductive system MP:0005389 9.73 APC BRCA2 COL4A2 IL2 MDM2 MYC
19 vision/eye MP:0005391 9.28 ABCG2 APC COL4A2 IL2 PLG RB1

Drugs & Therapeutics for Ocular Cancer

Drugs for Ocular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3 154-93-8 2578
2
Povidone-iodine Approved Phase 3 25655-41-8
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
4
Iodine Approved, Investigational Phase 3 7553-56-2 807
5
Povidone Approved Phase 3 9003-39-8 131751496
6
Cadexomer iodine Experimental Phase 3 94820-09-4
7 O(6)-benzylguanine Phase 3
8 Antibiotics, Antitubercular Phase 3
9 Angiogenesis Inhibitors Phase 3
10 Antineoplastic Agents, Immunological Phase 3
11 Mitogens Phase 3
12 Anti-Bacterial Agents Phase 3
13 Endothelial Growth Factors Phase 3
14
Tramadol Approved, Investigational Phase 1, Phase 2 27203-92-5 33741
15
Ibuprofen Approved Phase 1, Phase 2 15687-27-1 3672
16
Guaifenesin Approved, Investigational, Vet_approved Phase 1, Phase 2 93-14-1 3516
17
Methadone Approved Phase 1, Phase 2 76-99-3 4095
18
Melphalan Approved Phase 2 148-82-3 4053 460612
19
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
20 Anti-Inflammatory Agents Phase 1, Phase 2
21 Cyclooxygenase Inhibitors Phase 1, Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
23 Antirheumatic Agents Phase 1, Phase 2
24 Analgesics, Non-Narcotic Phase 2
25 Interleukin-2 Phase 2
26 Vaccines Phase 2
27 Analgesics Phase 2
28 Narcotics Phase 1, Phase 2
29 Analgesics, Opioid Phase 1, Phase 2
30 Respiratory System Agents Phase 1, Phase 2
31 Antitussive Agents Phase 1, Phase 2
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 1, Phase 2
33 D-methadone Phase 1, Phase 2
34 Anesthetics Phase 2
35 Technetium Tc 99m Sulfur Colloid Phase 2
36 Radiopharmaceuticals Phase 2
37 Alkylating Agents Phase 2
38 Immunosuppressive Agents Phase 2
39 Immunologic Factors Phase 2
40 topoisomerase I inhibitors Phase 2
41
Pembrolizumab Approved Phase 1 1374853-91-4
42
Doxycycline Approved, Investigational, Vet_approved Phase 1 564-25-0 54671203
43 Cola Phase 1
44 Anti-Infective Agents Phase 1
45 Antiprotozoal Agents Phase 1
46 Antiparasitic Agents Phase 1
47 Antimalarials Phase 1
48
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
49
tannic acid Approved 1401-55-4
50 Calamus

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
2 Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema Active, not recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
3 Post-Operative Pain Relief Following Insertion of Radioactive Plaque for Choroidal Melanoma: Randomised Control Trial of Tramadol Vs Ibuprofen: A Pilot Study Unknown status NCT00111046 Phase 1, Phase 2 Ibuprofen;Tramadol
4 Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
5 A Phase I/II Study of D-Methadone in Patients With Chronic Pain Completed NCT00588640 Phase 1, Phase 2 d-Methadone;D-methadone;placebo
6 Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases: a Randomized Phase II Clinical Trial Recruiting NCT03028337 Phase 2
7 Sentinel Lymph Node Localization and Biopsy for Sebaceous Gland Carcinoma of the Eyelid Recruiting NCT00832429 Phase 2 Tc99m-Sulfur colloid
8 A Phase II Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma, With Randomization Depending on the Site of Relapse or on Previous Treatment Not yet recruiting NCT04455139 Phase 2 Topotecan;Melphalan
9 Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Withdrawn NCT01151748 Phase 2
10 Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
11 A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors Recruiting NCT03435952 Phase 1 Pembrolizumab;Doxycycline
12 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
13 Postoperative Pain of General Anesthesia in Orbital Disease and Ocular Tumor Unknown status NCT02704715
14 New Biopsy Technique for Uveal Melanoma Completed NCT01924923
15 Quality of Life of Eye Amputated Patients in Denmark Completed NCT01072253
16 Social-Psychological Aspects of Survivorship in Cancer Patients After Orbital Exenteration: Issues Stemming From Alterations of Normal Facial Appearance Completed NCT00601744
17 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
18 Dynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit. Recruiting NCT01653080
19 Early Non-Invasive Ventilation in Patients With Hypoxemic Respiratory Failure and Hematological Malignancies: A Prospective Randomized Controlled Trial Recruiting NCT02464696
20 Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm Not yet recruiting NCT04695015

Search NIH Clinical Center for Ocular Cancer

Cochrane evidence based reviews: eye neoplasms

Genetic Tests for Ocular Cancer

Anatomical Context for Ocular Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Cancer:

19
Eye

MalaCards organs/tissues related to Ocular Cancer:

40
Eye, Bone Marrow, Brain, Retina, Colon, Prostate, Endothelial

Publications for Ocular Cancer

Articles related to Ocular Cancer:

(show top 50) (show all 91)
# Title Authors PMID Year
1
Single shot echo planar imaging (ssEPI) vs single shot turbo spin echo (ssTSE) DWI of the orbit in patients with ocular melanoma. 42
33264035 2021
2
Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres. 42
33183739 2020
3
CYFRA21-1/TG ratio as an accurate risk factor to predict eye metastasis in nasopharyngeal carcinoma: A STROBE-compliant article. 42
33181649 2020
4
A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. 61
33276309 2021
5
Animal-Based Measurements to Assess the Welfare of Dairy Cull Cows during Pre-Slaughter. 61
33020384 2020
6
High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. 61
33066024 2020
7
Response to the editorial titled "Public health strategy vs. golden standard for ocular cancer care in Brazil" by Neto, RB. 61
33084823 2020
8
[Management of ocular cancer during COVID-19 pandemic]. 61
32389526 2020
9
TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models. 61
32143295 2020
10
Public health strategy vs. golden standard for ocular cancer care in Brazil. 61
32130305 2020
11
Feline ocular post-traumatic sarcomas: Current understanding, treatment and monitoring. 61
31446864 2019
12
Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. 61
31200439 2019
13
Contemporary management of retinoblastoma in the context of a low-resource country. 61
31187745 2019
14
The Amazon Ocular Oncology Center: The first three years. 61
30698230 2019
15
Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference. 61
30652059 2019
16
Retinoblastoma, the visible CNS tumor: A review. 61
29314142 2019
17
Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers. 61
29742327 2018
18
The distinguished Austrian ophthalmologist Ernst Fuchs (1851-1930) and the "sarcom des uvealtractus". 61
30570892 2018
19
Imaging Techniques in the Diagnosis and Management of Ocular Tumors: Prospects and Challenges. 61
30187172 2018
20
Preimplantation genetic diagnosis as a strategy to prevent having a child born with an heritable eye disease. 61
29781739 2018
21
Wilhelm Fabricius von Hilden (1560-1634): The Pioneer of German Surgery. 61
29473453 2018
22
The distinguished Greek born, French ophthalmologist Photinos Panas (1832-1903) and his views on ocular cancer. 61
30003766 2018
23
Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: in vitro study. 61
29707895 2018
24
Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies. 61
29593251 2018
25
The management of retinoblastoma. 61
29321667 2018
26
Antonio Scarpa (1752-1832) and his study on ocular cancer. 61
29552793 2018
27
Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing. 61
29121185 2017
28
Technical Note: Dosimetric characteristics of the ocular beam line and commissioning data for an ocular proton therapy planning system at the Proton Therapy Center Houston. 61
28975637 2017
29
Characterization of Eyeball Loss in Four Cities of Colombia. 61
29152434 2017
30
The beginning of using X-rays and the evolution of equipment for the treatment of ocular cancer. 61
28315914 2017
31
Medical History in the Hellenic Journal of Nuclear Medicine. 61
28426839 2017
32
RB1 gene mutations in Argentine retinoblastoma patients. Implications for genetic counseling. 61
29261756 2017
33
Absent MicroRNAs in Different Tissues of Patients with Acquired Cardiomyopathy. 61
27475403 2016
34
WO3/Pt nanoparticles promote light-induced lipid peroxidation and lysosomal instability within tumor cells. 61
26788907 2016
35
Views on ocular cancer in Arabo-Islamic medicine and the leading influence of the ancient Greek medicine. 61
27061559 2016
36
Global gene deregulations in FASN silenced retinoblastoma cancer cells: molecular and clinico-pathological correlations. 61
25958981 2015
37
Drosophila as a Potential Model for Ocular Tumors. 61
27172095 2015
38
[Epidemiological and clinical characteristics of primary ocular cancers in blacks: our experience with 111 cases]. 61
25530349 2015
39
Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma. 61
28003818 2015
40
Chebulagic acid from Terminalia chebula causes G1 arrest, inhibits NFκB and induces apoptosis in retinoblastoma cells. 61
25169718 2014
41
The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): overview and results of the research prioritisation survey process. 61
25056971 2014
42
Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients. 61
24417420 2014
43
Uveal melanoma: A pathologist's perspective and review of translational developments. 61
24508696 2014
44
MicroRNA-21 Down-regulates Rb1 Expression by Targeting PDCD4 in Retinoblastoma. 61
25520758 2014
45
Local chemotherapeutic agents for the treatment of ocular malignancies. 61
24112549 2014
46
Abnormal odontogenesis following management of childhood cancer (retinoblastoma): review and a new variant. 61
23811674 2013
47
The pathology of ocular cancer. 61
23154492 2013
48
Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. 61
23441619 2013
49
Molecular Insights on Post-chemotherapy Retinoblastoma by Microarray Gene Expression Analysis. 61
24092970 2013
50
[The application of serum free medium in the research of isolating cancer stem cells]. 61
23141583 2012

Variations for Ocular Cancer

Cosmic variations for Ocular Cancer:

9 (show all 49)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM86647435 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13:48459835-48459835 36
2 COSM86634466 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13:48342715-48342715 36
3 COSM86624550 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13:48379594-48379594 36
4 COSM86651352 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13:48380084-48380084 36
5 COSM86624126 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13:48362847-48362847 36
6 COSM86624950 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13:48373460-48373460 36
7 COSM86626226 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13:48367512-48367512 36
8 COSM86647609 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13:48456351-48456351 36
9 COSM86625405 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13:48381414-48381414 36
10 COSM86626205 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13:48379624-48379624 36
11 COSM86628490 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 36
12 COSM86642443 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13:48476707-48476707 36
13 COSM86636835 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13:48465203-48465203 36
14 COSM86633737 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13:48367521-48367521 36
15 COSM86624252 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13:48373493-48373493 36
16 COSM86631349 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13:48463782-48463782 36
17 COSM86627680 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13:48373443-48373443 36
18 COSM86638492 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13:48376916-48376916 36
19 COSM86629052 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13:48459687-48459687 36
20 COSM86640644 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13:48380210-48380210 36
21 COSM86635450 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13:48459780-48459780 36
22 COSM86637950 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13:48342597-48342597 36
23 COSM86629160 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13:48345108-48345108 36
24 COSM86624395 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13:48473394-48473394 36
25 COSM86640590 RB1 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 36
26 COSM86656361 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13:48367536-48367536 36
27 COSM86630951 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13:48381402-48381402 36
28 COSM86631559 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13:48367604-48367604 36
29 COSM86632900 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13:48459790-48459790 36
30 COSM150688162 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 36
31 COSM86649095 RB1 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 36
32 COSM86626876 RB1 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 36
33 COSM86637333 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13:48342675-48342675 36
34 COSM86632739 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13:48456350-48456350 36
35 COSM86630352 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13:48364889-48364889 36
36 COSM86632080 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 36
37 COSM86654450 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13:48463776-48463776 36
38 COSM86640621 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13:48379651-48379651 36
39 COSM86648958 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13:48380237-48380237 36
40 COSM87132285 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 36
41 COSM148932691 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 36
42 COSM91859716 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 36
43 COSM87804005 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 36
44 COSM87804055 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 36
45 COSM134990158 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 36
46 COSM134614922 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 36
47 COSM134990112 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 36
48 COSM134614978 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 36
49 COSM91859752 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 36

Expression for Ocular Cancer

Search GEO for disease gene expression data for Ocular Cancer.

Pathways for Ocular Cancer

Pathways related to Ocular Cancer according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 TP53 RB1 MYC MDM2 IL2 COL4A2
2
Show member pathways
12.82 TP53 RB1 MYC MDM2 BRCA2 APC
3
Show member pathways
12.79 TP53 MYC MDM2 H2AC18 APC
4
Show member pathways
12.75 TP53 RB1 PLG MYC MDM2 IL2
5
Show member pathways
12.72 TP53 RB1 MYC BRCA2 APC
6
Show member pathways
12.62 XPA TP53 RB1 MYC MDM2 BRCA2
7 12.45 XPA TP53 RB1 MDM2 BRCA2
8
Show member pathways
12.32 TP53 RB1 MYC MIR17 MDM2
9 12.29 TP53 RB1 MYC IL2
10 12.29 TP53 MYC MIR199A1 MIR17 MDM2 APC
11 12.28 TP53 RB1 MYC MDM2 IL2 COL4A2
12 12.27 TP53 RB1 MYC MDM2 APC
13 12.12 TP53 RB1 MYC MDM2
14 12.07 SOX2 POU5F1 MYC APC
15
Show member pathways
12.05 TP53 SOX2 POU5F1 MYC APC
16 12.02 TP53 RB1 MDM2 APC
17 11.96 TP53 RB1 MYC IL2
18 11.95 TP53 RB1 MYC MDM2 BRCA2
19 11.93 TP53 MYC MDM2 APC
20 11.79 TP53 RB1 MYC COL4A2
21
Show member pathways
11.76 TP53 RB1 BRCA2
22 11.75 TP53 MDM2 IL2
23 11.72 TP53 RB1 MYC MDM2
24 11.69 XPA TP53 MDM2
25 11.67 XPA TP53 RB1 MDM2
26 11.6 TP53 RB1 MYC MDM2
27 11.6 TP53 RB1 MYC MDM2 APC
28 11.55 TP53 MDM2 APC
29 11.52 TP53 RB1 IL2
30 11.51 TP53 MYC COL4A2
31 11.44 TP53 MYC MDM2
32 11.35 RB1 MYC BRCA2
33 11.22 TP53 RB1 MYC MDM2
34
Show member pathways
11.01 TP53 MYC MDM2
35
Show member pathways
10.66 SOX2 POU5F1
36 10.27 TP53 RB1 MYC MDM2

GO Terms for Ocular Cancer

Cellular components related to Ocular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 XPA U2AF1 TP53 SOX2 RB1 POU5F1
2 transcription factor complex GO:0005667 8.92 TP53 SOX2 RB1 POU5F1

Biological processes related to Ocular Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.01 TP53 SOX2 RB1 POU5F1 MYC MDM2
2 cellular response to DNA damage stimulus GO:0006974 9.92 XPA TP53 MYC BRCA2 APC
3 negative regulation of gene expression GO:0010629 9.8 TP53 RB1 POU5F1 MIR17 MDM2
4 cellular response to hypoxia GO:0071456 9.67 TP53 MYC MIR17 MDM2
5 nucleotide-excision repair GO:0006289 9.61 XPA TP53 BRCA2
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.56 TP53 SOX2 RB1 POU5F1 MYC MDM2
7 UV protection GO:0009650 9.55 XPA MC1R
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.51 MIR199A1 MIR17
9 UV-damage excision repair GO:0070914 9.49 XPA MC1R
10 cellular response to UV-C GO:0071494 9.48 TP53 MDM2
11 endodermal cell fate specification GO:0001714 9.46 SOX2 POU5F1
12 chromosome organization GO:0051276 9.43 TP53 MYC BRCA2
13 response to gamma radiation GO:0010332 9.33 TP53 MYC BRCA2
14 cellular response to actinomycin D GO:0072717 9.32 TP53 MDM2
15 cell cycle arrest GO:0007050 9.02 TP53 SOX2 RB1 MYC APC

Molecular functions related to Ocular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.13 TP53 RB1 MDM2
2 ubiquitin protein ligase binding GO:0031625 9.1 TP53 RB1 POU5F1 MDM2 MC1R APC

Sources for Ocular Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....